IBD remission isn't the whole story — patients need more than mucosal healing

Achieving mucosal healing and normal lab markers in inflammatory bowel disease (IBD) doesn't guarantee patients actually feel well. A new conceptual framework published in eClinicalMedicine — developed by researchers from the University of São Paulo and the University of Manitoba — proposes applying the "treatable traits" model to IBD, organizing persistent, modifiable mechanisms into three clinical domains: gastrointestinal/intrinsic traits, extraintestinal/comorbidity traits, and psychological/behavioral traits.

The framework addresses a well-known but underappreciated gap: roughly one-third of IBD patients in endoscopic remission still report chronic fatigue, abdominal pain, anxiety, and sleep disturbances. Experts stress that mucosal healing tells only the "biological story" of the disease, while patients' lived experience — what they can actually do and feel — often goes unaddressed in standard care.

Key Takeaways:

• Only 40–50% of IBD patients maintain complete remission with conventional monotherapy
• The treatable traits model complements — rather than replaces — existing STRIDE-II consensus targets, enabling more individualized, precision-based intervention
• Basic tools (blood counts, dynamometry, brief mental health questionnaires) can implement the model without costly technology
• Infusion centers can double as screening hubs using patient-reported outcome tools during treatment sessions

Why it matters: Treating IBD to remission on paper isn't enough if patients are still suffering. This framework pushes clinicians to broaden their definition of success — from biomarkers to real-world functional recovery.